Figure S5 to Figure S43. Organ-specific (i.e., skin, endocrine, gastrointestinal, hepatic, and renal diseases) irAEs (all grade and high grade) associated with anti-PD-1 and anti-PD-L1, anti-PD-1, nivolumab, pembrolizumab, anti-PD-L1, atezolizumab, and durvalumab at all dosages. This evidence concerns the gene PDCD1 and kidney disorder.